The Saladax Board of Directors consists of the President and Chief Executive Officer, Company founders and the following individuals:
Edward L. Erickson, President & Chief Executive Officer*
Salvatore J. Salamone, Ph.D., Founder & Chief Scientific Officer*
Adrienne Choma, Esq., Founder & Vice President, Marketing & Sales*
Gregory Critchfield, M.D. is the Chairman of the Board at Saladax. Dr. Critchfield most recently served as President of Myriad Genetic Laboratories, Inc. which he built into one of worlds leading molecular diagnostic companies. Prior to joining Myriad in 1998, he served as Chief Medical and Science Officer at Corning Clinical Laboratories which became Quest Diagnostics, Inc., with responsibility for science medicine and innovation. Dr. Critchfield also served on the faculty of three medical schools University of Minnesota, Wayne State University and Duke University and worked as a practicing clinical pathologist with Intermountain Healthcare for nine years. He chaired the Governor's State Advisory Council on Science and Technology for the state of Utah in 2007. Dr. Critchfield served as a reviewer and study section chair for the NIH for over 15 years in biomedical computing programs for SBIR, STTR and R01 programs. He has served and is serving as an independent director in industry association and various other life science companies. Dr. Critchfield received a Bachelors Degree in Microbiology with a minor in Chemistry from Brigham Young University in 1976, an MD degree from the University of Utah in 1980, and a masters degree in Biophysical Sciences at the University of Minnesota in 1985.
Joel Gross is a veteran of more than 25 years in finance and was a highly ranked Wall Street analyst for seven years. He currently is a consultant and investor, and is a guest speaker at several universities. Mr. Gross graduated with honors from Rutgers University with a B.S. in economics and has an M.B.A. with honors from Penn State.
Kevin M. Harter is a co-founder and Senior Vice President of the Life Science Greenhouse, a public-private partnership, where he manages a portfolio of early-stage biotech, medical device, and diagnostic companies. From 2007-2011, Harter also served as Chairman of Saladax Biomedical Inc., an LSG-portfolio company where he led multiple, successful funding rounds and strategic deals for the company. He has represented the LSG on various for-profit boards, and as interim senior management when appropriate. Harter previously co-founded Keystone Medical Systems in 1990 and managed it through significant growth until its acquisition by publicly-held Continental Medical Systems. Prior to Keystone, Harter held several positions within the Pennsylvania Blue Shield organization, including Vice President, Technology. Harter contributed significantly to the development of the field of electronic claims, electronic medical records, and physician practice management. He has held more than two dozen board seats in technology and financial companies. Recognition for his professional and volunteer achievements includes the Entrepreneur of the Year award and the Alumni Fellow and Philip Philip Mitchell Service Awards from the Pennsylvania State University. He holds a B.S. and MBA from the Pennsylvania State University.
James F. Hensel is Senior Vice President at Columbia Ventures Corporation (CVC). Mr. Hensel founded the medical device company, HemCon, Inc., was a partner at the law firm of Ater Wynne in Portland, Oregon, and most recently served as CEO and President of Metro One Telecommunications, Inc. (PK:INFO). He is a board member of several private and nonprofit companies. Mr. Hensel holds a B.A. from Harvard University and a J.D. from Willamette University College of Law.
Enrico Petrillo, M.D. is Managing Director of Excel Venture Management. He has over 20 years of experience as a venture investor, healthcare consultant, entrepreneur, and physician. He initiated multiple investments in life science companies, including Aileron, MedVentive, US Genomics, BioTrove, Quovadx (now Healthvision), eBenX (acquired by SHPS), and Morphotek (acquired by Eisai) and serves on multiple boards. Dr. Petrillo is a current advisor to the U.S. Department of Defense and serves as an Adjunct Assistant Professor of Medicine at Boston University. Dr. Petrillo earned both his undergraduate and M.D. degrees from Tufts University, and completed his internship and residency at Harvard-affiliated hospitals in Boston.
*Executive director of the board as well